Gilead Sciences (GILD) Stock Price
Gilead Sciences Price
Over the last 19 years Gilead Sciences grew revenue by 12.7% annually, reaching 29.44 B USD. Earnings per share have grown at 12.1% per year over the last 18 years. For Gilead Sciences, the net margin of 28.9% is up versus 22.8% a few years ago. At today's price the dividend yield works out to roughly 2.17%. The payout ratio is around 47% of earnings. The dividend has grown at 9.4% per year over the past 10 years. The consensus 12-month price target for Gilead Sciences is 155.00 USD, about 6.5% above where the stock trades today. Of 37 analysts, 30 rate the stock a buy — an overall Buy consensus. Gilead Sciences's share price has gained 29.4% over the last twelve months. The stock trades about 31% above its 52-week low.
Gilead Sciences stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Gilead Sciences over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Gilead Sciences stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Gilead Sciences's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Gilead Sciences Price |
|---|---|
| 9/15/2026 | 145.60 USD |
| 9/14/2026 | 145.87 USD |
| 9/11/2026 | 143.81 USD |
| 9/10/2026 | 144.37 USD |
| 9/9/2026 | 145.65 USD |
| 9/8/2026 | 146.04 USD |
| 9/4/2026 | 150.79 USD |
| 9/3/2026 | 151.22 USD |
| 9/2/2026 | 149.61 USD |
| 9/1/2026 | 149.92 USD |
| 8/31/2026 | 146.25 USD |
| 8/28/2026 | 146.09 USD |
| 8/27/2026 | 148.87 USD |
| 8/26/2026 | 148.09 USD |
| 8/25/2026 | 148.77 USD |
| 8/24/2026 | 145.90 USD |
| 8/21/2026 | 146.12 USD |
| 8/20/2026 | 143.44 USD |
| 8/19/2026 | 146.92 USD |
| 8/18/2026 | 142.89 USD |
| 8/14/2026 | 138.36 USD |
| 8/13/2026 | 138.14 USD |
| 8/12/2026 | 135.87 USD |
| 8/11/2026 | 135.77 USD |
| 8/10/2026 | 133.60 USD |
| 8/7/2026 | 133.21 USD |
| 8/6/2026 | 130.86 USD |
| 8/5/2026 | 130.96 USD |
| 8/4/2026 | 130.59 USD |
| 8/3/2026 | 131.15 USD |
Gilead Sciences Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Gilead Sciences Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.USD |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESB |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 32.64 | 30.39 | 26.11 | 22.13 | 22.45 | 24.69 | 27.31 | 27.28 | 27.12 | 28.75 | 29.44 | 30.70 | 32.71 | 34.41 | 36.92 | 39.00 |
| 31.13 | -6.89 | -14.09 | -15.24 | 1.46 | 9.98 | 10.60 | -0.09 | -0.60 | 6.04 | 2.39 | 4.28 | 6.54 | 5.19 | 7.28 | 5.66 |
| 87.73 | 85.98 | 83.26 | 78.07 | 79.18 | 81.48 | 75.82 | 79.26 | 100.00 | 78.26 | 78.83 | 78.83 | 78.83 | 78.83 | 78.83 | 78.83 |
| 28.63 | 26.13 | 21.74 | 17.27 | 17.77 | 20.12 | 20.70 | 21.62 | 27.12 | 22.50 | 23.21 | 24.20 | 25.78 | 27.12 | 29.10 | 30.75 |
| 22.19 | 17.63 | 14.12 | 8.20 | 6.16 | 4.07 | 9.92 | 7.33 | 7.61 | 1.67 | 10.82 | 0.45 | 16.59 | 17.71 | 20.19 | 21.87 |
| 68.00 | 58.02 | 54.10 | 37.06 | 27.42 | 16.49 | 36.32 | 26.87 | 28.05 | 5.80 | 36.75 | 1.46 | 50.72 | 51.47 | 54.69 | 56.07 |
| 18.11 | 13.50 | 4.63 | 5.46 | 5.39 | 0.12 | 6.23 | 4.59 | 5.67 | 0.48 | 8.51 | -0.55 | 12.42 | 13.38 | 15.11 | 16.43 |
| 49.64 | -25.44 | -65.72 | 17.87 | -1.26 | -97.72 | 4,960.98 | -26.23 | 23.37 | -91.53 | 1,672.92 | -106.50 | -2,345.39 | 7.78 | 12.87 | 8.74 |
| 1.72 | 1.84 | 2.08 | 2.28 | 2.52 | 2.72 | 2.84 | 2.92 | 3.00 | 3.08 | 3.16 | 3.28 | 3.38 | 3.48 | – | – |
| – | 6.98 | 13.04 | 9.62 | 10.53 | 7.94 | 4.41 | 2.82 | 2.74 | 2.67 | 2.60 | 3.80 | 3.05 | 2.96 | – | – |
| 1.47 | 1.33 | 1.31 | 1.30 | 1.27 | 1.26 | 1.26 | 1.26 | 1.26 | 1.26 | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Gilead Sciences generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Gilead Sciences retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Gilead Sciences's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Gilead Sciences has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Gilead Sciences's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Gilead Sciences stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Gilead Sciences Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Gilead Sciences business model & stock analysis
Gilead Sciences SWOT Analysis
Strengths
Gilead Sciences Inc has several notable strengths that contribute to its success in the pharmaceutical industry. Firstly, the company possesses a strong portfolio of innovative and high-quality drugs, particularly in the fields of antiviral and antifungal medications. These products have gained considerable recognition and have established Gilead Sciences as a trusted name in the industry.
Another strength of Gilead Sciences Inc lies in its robust research and development capabilities. The company invests heavily in scientific advancements and clinical trials, allowing them to discover breakthrough treatments and maintain a competitive edge. This commitment to innovation has resulted in numerous successful drug launches and a strong pipeline for future growth.
Weaknesses
Despite its strengths, Gilead Sciences Inc faces certain weaknesses that it needs to address. One aspect is its heavy reliance on a limited number of key products for a significant portion of its revenue. This creates a vulnerability to fluctuations in demand or potential patent expirations, which could impact the company's financial performance.
Additionally, Gilead Sciences has faced criticism for the high cost of some of its medications, particularly those treating chronic conditions such as HIV. The pricing strategy has led to public scrutiny and potential challenges in terms of affordability and accessibility for patients. Addressing these concerns could help improve the company's reputation and customer relationships.
Opportunities
Gilead Sciences Inc has several opportunities to further expand its market presence and generate growth. One major opportunity lies in the emerging markets, where there is a growing demand for pharmaceutical products. By tapping into these regions and adapting their business strategies accordingly, Gilead Sciences can extend its reach and increase its market share.
The company also has the opportunity to explore potential partnerships or collaborations with other pharmaceutical firms or research institutions. Such alliances can lead to knowledge sharing, joint development of new drugs, and shared resources, ultimately enhancing Gilead Sciences' product offerings and competitive advantage.
Threats
Gilead Sciences Inc faces certain threats that could hinder its growth and profitability. One prominent threat is the intense competition within the pharmaceutical industry. Rival companies continuously strive to innovate and launch similar products, thereby reducing Gilead Sciences' market share and pricing power.
Moreover, regulatory and legal challenges present additional threats. Strict regulations, patent disputes, and changes in healthcare policies can impact the company's ability to market and distribute its drugs effectively. To mitigate these threats, Gilead Sciences must continually adapt and comply with evolving regulations while safeguarding its intellectual property rights.
Gilead Sciences Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Gilead Sciences Segments
Gilead Sciences Revenue by Segment (1/2)
3 Years
5 Years
Max
Details
Gilead Sciences Revenue by Segment (2/2)
3 Years
5 Years
Max
Details
Gilead Sciences Revenue by Region
3 Years
Max
Details
Gilead Sciences Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Gilead Sciences historical P/E ratio, EBIT multiple, and P/S ratio
Gilead Sciences annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Gilead Sciences's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Gilead Sciences's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Gilead Sciences's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Gilead Sciences shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Gilead Sciences stock splits
Since 2001, a total of 32 shares have been converted from one Gilead Sciences share.
Gilead Sciences Dividend History
12 years of dividend payments · 10 consecutive increases
Gilead Sciences dividend history and estimates
Max
Details
Gilead Sciences dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Gilead Sciences forecasts and price targets in September 2026
Analyst Price Targets 2026Gilead Sciences Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/5/2026 | Maintained | Sector Perform | 48 | |
| 8/5/2026 | Maintained | Buy | 58 | |
| 8/5/2026 | Maintained | Overweight | 38 | |
| 7/29/2026 | Maintained | Equal Weight | 62 | |
| 7/27/2026 | Maintained | Overweight | 46 | |
| 7/21/2026 | Downgrade | OutperformMarket Perform | – | |
| 7/8/2026 | Maintained | Overweight | 46 | |
| 7/7/2026 | Maintained | Buy | – | |
| 7/7/2026 | Maintained | Sector Perform | 48 | |
| 7/6/2026 | Upgrade | HoldBuy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Gilead Sciences Earnings Calls
Gilead Sciences Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/6/2026 | -7.43USD | - | 7.55 BUSD | - | 2026 Q2 |
| 5/7/2026 | 1.94USD | - | 7.04 BUSD | - | 2026 Q1 |
| 2/10/2026 | 1.85USD | - | 7.85 BUSD | - | 2025 Q4 |
| 11/7/2024 | 1.62USD | - | 7.11 BUSD | - | 2024 Q3 |
| 4/25/2024 | 1.85USD | - | 6.61 BUSD | - | 2024 Q1 |
| 1/31/2024 | 1.82USD | - | 7.22 BUSD | - | 2023 Q4 |
| 7/31/2023 | 1.74USD | - | 6.41 BUSD | - | 2023 Q2 |
| 4/26/2023 | 1.69USD | - | 6.12 BUSD | - | 2023 Q1 |
| 1/30/2023 | 1.52USD | - | 6.75 BUSD | - | 2022 Q4 |
| 10/27/2022 | 1.45USD | 1.90USD | 6.22 BUSD | - | 2022 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Gilead Sciences stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Gilead Sciences shareholder structure
| % | Name |
|---|---|
9.60064% | |
9.48295% | |
6.42668% | |
6.04843% | |
5.72958% | |
4.80004% |
Gilead Sciences Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
29.90% | SEC ↗ | |
24.70% | SEC ↗ | |
12.00% | SEC ↗ | |
10.10% | SEC ↗ | |
9.50% | SEC ↗ | |
8.20% | SEC ↗ | |
7.51% | SEC ↗ | |
6.50% | SEC ↗ | |
6.27% | SEC ↗ | |
6.27% | SEC ↗ |
Gilead Sciences Executives and Management Board
14 members · avg. age 63 · 50 % women
Mr. Daniel O'Day (60)
Chairman of the Board, Chief Executive Officer · since 2019
23.69 M USD
Management
Ms. Johanna Mercier (55)
Chief Commercial Officer
Mr. Andrew Dickinson (55)
Chief Financial Officer
Ms. Keeley Wettan
Executive Vice President, General Counsel, Legal & Compliance
Ms. Erin Burkhart (46)
Senior Vice President, Principal Accounting Officer, Controller
Dr. Dietmar Berger (62)
Chief Medical Officer
Board of Directors
Dr. Ted Love (66)
Independent Director
Mr. Anthony Welters (70)
Lead Independent Director
Ms. Kelly Kramer (57)
Independent Director
Dr. Jacqueline Barton (72)
Independent Director
Dr. Sandra Horning (76)
Independent Director
Mr. Harish Manwani (71)
Independent Director
Gilead Sciences Supply Chain
Gilead Sciences Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.01 | -0.06 | 0.45 | ||
| 2 | 0.73 | 0.74 | 0.35 | ||
| 3 | 0.72 | 0.50 | 0.34 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | Galapagos NV | 0.77 | — | — | |
| 2 | 0.82 | 0.52 | — | ||
| 3 | Japan Tobacco Inc. | 0.42 | 0.28 | — | |
| 4 | Novartis AG | -0.31 | -0.08 | — | |
| 5 | Roche Holding AG | 0.30 | 0.21 | — |
Frequently asked questions about Gilead Sciences
Gilead Sciences Inc is a biopharmaceutical company with a diversified business model. Its primary focus is on the research, development, and commercialization of innovative medications to treat and prevent life-threatening diseases. Gilead operates in multiple therapeutic areas, including HIV/AIDS, liver diseases, hematology/oncology, respiratory, cardiovascular, and viral infections. The company's business model revolves around discovering and designing new drugs, conducting clinical trials, obtaining regulatory approvals, manufacturing, marketing, and distribution of its pharmaceutical products. Through strategic collaborations and acquisitions, Gilead continuously expands its portfolio and aims to improve the quality of life for patients worldwide.
Gilead Sciences Inc is primarily active in the pharmaceutical industry.
The main competitors of Gilead Sciences Inc in the market include renowned companies like AbbVie, Bristol-Myers Squibb, and Merck & Co. These pharmaceutical giants operate in similar therapeutic areas and engage in the research, development, and commercialization of innovative medicines. At present, Gilead Sciences Inc faces competition in the fields of antiviral drugs, liver diseases, HIV/AIDS treatments, and oncology from these prominent industry players.
Gilead Sciences Inc, a leading biopharmaceutical company, was founded in 1987 by Dr. Michael L. Riordan in Foster City, California, USA. It specializes in discovering, developing, and commercializing innovative medicines to address unmet medical needs. Gilead has a rich history of pioneering breakthrough treatments for critical diseases such as HIV/AIDS, hepatitis, and other viral infections. With a mission to advance patient care globally, Gilead has expanded its portfolio through strategic acquisitions and collaborations, constantly striving to improve and save lives. Today, Gilead Sciences Inc remains committed to research, development, and manufacturing of transformative therapies across various therapeutic areas.
Gilead Sciences Inc has achieved several significant milestones throughout its history. It gained global recognition with the development of groundbreaking antiviral drugs such as Sovaldi and Harvoni, revolutionizing the treatment of hepatitis C. The company also made remarkable progress in the field of HIV, introducing a single-tablet regimen named Genvoya, providing convenient and effective therapy. Gilead Sciences Inc further expanded its therapeutic areas, bringing forth innovative treatments for life-threatening diseases like cancer and autoimmune disorders. Moreover, it received approval for its antiviral drug, remdesivir, as a treatment for COVID-19. These milestones solidify Gilead Sciences Inc's position as a leader in the pharmaceutical industry.
Gilead Sciences Inc is primarily present in various countries and regions worldwide. Some key locations where the company has a strong presence include the United States, Europe (including countries like Germany, France, and the United Kingdom), Asia-Pacific (including countries like Japan, Australia, and China), and Latin America (including countries like Brazil and Mexico). With a global footprint, Gilead Sciences Inc operates in multiple markets, providing its innovative biopharmaceutical products and therapies to patients across different continents.
Gilead Sciences Inc represents a commitment to improving the lives of patients through innovative research and development in the fields of life sciences and biotechnology. Their corporate philosophy emphasizes a patient-centered approach, scientific integrity, and a drive to address unmet medical needs. Gilead Sciences Inc focuses on developing breakthrough therapies and treatments to combat diseases such as HIV/AIDS, viral hepatitis, and other challenging illnesses. They prioritize collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality healthcare solutions. With a strong emphasis on scientific excellence and a dedication to addressing global health challenges, Gilead Sciences Inc continues to make a significant impact in the industry.
Analysts currently set an average price target of 153.33 USD for the Gilead Sciences stock (median: 155.00 USD), implying +5.1 % versus the latest price. The consensus is based on 37 analyst ratings.
37 analysts currently rate the Gilead Sciences stock: 30 recommend buying, 7 holding and 0 selling. For 2026, analysts expect Gilead Sciences to generate revenue of 30.70 B USD and earnings per share of -0.44 USD.
Converted at the current exchange rate, the Gilead Sciences share trades at 126.04 EUR (145.60 USD).
The Gilead Sciences share (GILD) is listed on 10 stock exchanges, including: NASDAQ (GILD), London (0QYQ.L), SIX (Zürich) (GILD.SW), XETRA (GIS.DE), Frankfurt (GIS.F), München (GIS.MU), Düsseldorf (GIS.DU), Hamburg (GIS.HM).
Gilead Sciences Inc is a biopharmaceutical company that develops innovative therapies for serious diseases such as HIV, hepatitis B and C, cancer, lung and liver diseases. The company is headquartered in Foster City, California and has been publicly traded since 1987. Gilead operates worldwide and has offices in more than 30 countries. The business model of Gilead Sciences is based on the development, manufacturing and marketing of innovative drugs. The company specializes in discovering chemicals that enable effective treatment of diseases. In recent years, Gilead Sciences has focused on the development of drugs for hepatitis C and HIV, which has contributed to significant revenue growth. Gilead Sciences' products are divided into three divisions: 1. Infectious Diseases: This division includes drugs for the treatment of HIV, hepatitis B and C, and other infectious diseases. The most well-known and successful drug is Viread, used for the treatment of HIV and hepatitis B. Another promising drug is Harvoni, a combination of two active ingredients used to treat hepatitis C. 2. Oncology: This division includes drugs for the treatment of various types of cancer, such as multiple myeloma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. The most well-known drug is Revlimid, used for the treatment of multiple myeloma and other types of cancer. 3. Inflammatory and respiratory diseases: This division includes drugs for the treatment of conditions such as rheumatoid arthritis, Crohn's disease, and emphysema. The most well-known drug is Remicade, used for the treatment of inflammatory bowel disease. In recent years, Gilead Sciences has established itself as a leading biopharmaceutical company through significant acquisitions and acquisitions. For example, in 2017, Kite Pharma, a company specializing in cancer immunotherapy, was acquired for $11.9 billion. This acquisition allowed Gilead Sciences to expand its portfolio of oncology drugs and strengthen its market position. Gilead Sciences' business model is based on a strong research and development department that continuously discovers and introduces new drugs to the market. Gilead Sciences has a broad pipeline of drugs in development to provide effective treatment for serious diseases to patients worldwide. The company works closely with regulatory authorities to expedite the approval of new drugs. Overall, Gilead Sciences Inc is an innovative and successful biopharmaceutical company specializing in the development and marketing of drugs for the treatment of serious diseases. The company has established itself as a leading provider in this field in recent years and will continue to play a crucial role in the development of new therapies in the future.
The expected revenue of Gilead Sciences is 30.70 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Gilead Sciences is -553.00 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Gilead Sciences is currently -329.89. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Gilead Sciences stock.
The price-to-sales ratio (P/S) of Gilead Sciences is currently 5.94. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Gilead Sciences stock.
The Eulerpool Quality Score for Gilead Sciences is 3/10.
The ISIN of Gilead Sciences is US3755581036. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Gilead Sciences is 885823. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Gilead Sciences is GILD. The ticker symbol is used to trade Gilead Sciences shares on the stock exchange.
Over the past 12 months, Gilead Sciences paid a dividend of 3.16 USD . This corresponds to a dividend yield of about 2.17 %. For the coming 12 months, Gilead Sciences is expected to pay a dividend of 3.38 USD.
The current dividend yield of Gilead Sciences is 2.17 %.
Gilead Sciences pays a dividend, distributed in the months of December, March, June, September.
Gilead Sciences paid dividends every year for the past 11 years.
For the upcoming 12 months, dividends amounting to 3.38 USD are expected. This corresponds to a dividend yield of 2.32 %.
Gilead Sciences is assigned to the 'Health' sector.
To receive the latest dividend of Gilead Sciences from 9/29/2026 amounting to 0.82 USD, you needed to have the stock in your portfolio before the ex-date on 9/15/2026.
The last dividend was paid out on 9/29/2026.
In the year 2025, Gilead Sciences distributed 3.16 USD as dividends.
The dividends of Gilead Sciences are distributed in USD.
Gilead Sciences stock
Gilead Sciences Peer Group
Gilead Sciences Ticker
Gilead Sciences FIGI
All fundamentals and in-depth analysis of Gilead Sciences
Our stock analysis for Gilead Sciences stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gilead Sciences. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.